Tenax Therapeutics (TENX) Non-Current Deferred Tax Liability (2015 - 2021)
Tenax Therapeutics (TENX) posted quarterly Non-Current Deferred Tax Liability of $211590.0 for Q3 2021, down 11.48% on a QoQ basis from $239039.0 in Q2 2021.
Tenax Therapeutics (TENX) Non-Current Deferred Tax Liability (2015 - 2021) Analysis & Trends
Tenax Therapeutics has reported Non-Current Deferred Tax Liability for 4 years, with the latest figure at $211590.0 in Q3 2021.
- Non-Current Deferred Tax Liability for Q3 2021 came in at $211590.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2021 was $211590.0 (changed N/A YoY), and the FY2020 annual result was $347.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability eased to $211590.0 in Q3 2021, from $239039.0 in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $239039.0 in Q2 2021 and troughed at $347.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 211,590.00 |
| Sep 30, 2021 | 211,590.00 |
| Jun 30, 2021 | 239,039.00 |
| Jun 30, 2021 | 239,039.00 |
| Dec 31, 2020 | 347.00 |
| Dec 31, 2020 | 347.00 |
| Sep 30, 2016 | 7.96 Mn |
| Sep 30, 2016 | 7.96 Mn |
| Jun 30, 2016 | 7.96 Mn |
| Jun 30, 2016 | 7.96 Mn |
| Dec 31, 2015 | 7.96 Mn |
| Dec 31, 2015 | 7.96 Mn |